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Abstract 
We have studied the effects of two non-nucleoside reverse transcriptase inhibitors (NNRTI), nitrophenyl phenyl sulfone (NPPS) and a potent 
derivative of oxathiin carboxanilide (UC-38), on enzymatically active molecular chimeras composed of complementary segments of the reverse 
transcriptases (RTs) of human immunodeficiency virus type 1 (HIV-I) and -2 (HIV-2). The substances inhibit only the DNA polymerase activity 
of HIV-1 RT with no effect on HIV-2 RT. The results uggest that there is a protein segment located between residues 158 and 190 that is critical 
for the inhibition by both compounds. However, there is probably asecond segment that resides between residues 192 and 202, as in the case of NPPS, 
or residues 203 and 224, as in the case of UC-38, that is also crucial for the sensitivity of HIV-I RT to both inhibitors. 
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1. Introduction 
Acquired immunodeficiency syndrome (AIDS) is 
caused by human immunodeficiency virus type 1 (HIV- 
1) or -2 (HIV-2). As is true for all retroviruses, a key 
process in the life cycle of the virus is the reverse tran- 
scription of the viral single-stranded RNA into double- 
stranded DNA. This process does not appear to be re- 
quired for normal cellular processes. First, the viral 
RNA is reverse transcribed into single-stranded DNA by 
the RNA-dependent DNA polymerase (RDDP) activity 
of reverse transcriptase (RT). Next, the RNA template 
is hydrolyzed by the ribonuclease H (RNase H) activity 
of the enzyme. Finally, the DNA serves as a template for 
the synthesis of the second DNA strand, catalyzed by the 
DNA-dependent DNA polymerase (DDDP) activity of 
the RT. 
Numerous compounds that inhibit the reverse tran- 
scription process have been found; some of them serve 
as anti-HIV drugs for the treatment of AIDS patients. 
Most of these inhibitors can be grouped into two distinct 
classes. The first group consists of nucleoside analogs 
that, when incorporated into the nascent DNA by the 
RT cause premature chain terminations. Among the 
drugs included in this class are 3'-azido-2',3'-dideoxythy- 
midine (AZT), 2',3' dideoxycytidine (ddC) and 2",3' did- 
eoxyinosine (ddI). These substances inhibit 
HIV-1 RT and HIV-2 RT to about the same extent [1]. 
A second class of inhibitors are complex aromatic sub- 
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stances that are potent inhibitors of HIV-1 RT but have 
no effect on HIV-2 RT. These non-nucleoside inhibitors 
are structurally diverse and include nevirapine [2], pyrid- 
inone derivatives [3], tetrahydroimidazo [4,5,1-jk] [1,4]- 
benzo diazepin-2(1H) one and-thione (TIBO) derivative 
[4], and HEPT [5,6]. Surprisingly, these inhibitors share 
functional similarities, despite their chemical diversity. 
Thus, HIV-1 RT mutants how a cross-resistance to sev- 
eral members of this group of inhibitors (see [7] for re- 
view). More recently, the calanolides have been identi- 
fied as a second type of non-nucleoside inhibitors of 
HIV-1 RT (NNRTI).  Hence, a TIBO- and nevirapine- 
resistant mutant strain of HIV-1 was found to be inhib- 
ited by calanolide A [8]. 
Several studies have shown that Tyr 181 and Tyr 188 in 
HIV-1 RT are the main amino acid residues that interact 
with the first group of NNRTI  (e.g. TIBO and nevi- 
rapine), whereas Lys 1°3 is involved also to a certain ex- 
tent with the inhibition [7,9]. These results are based 
mainly on the behavior of HIV-1 RT mutants derived 
from either clinical isolates of drug-resistant virions or 
from in vitro mutagenesis. Another approach for localiz- 
ing the interaction sites with the inhibitors is to use enzy- 
matically active molecular chimeras composed of com- 
plementary segments of the inhibitor-sensitive HIV-1 RT 
and the inhibitor-resistant HIV-2 RT. The inhibition 
pattern with calanolide A provided evidence that there 
are two regions in HIV-1 RT molecules that are critical 
for the inhibition. The first domain is located between 
amino acid residues 94 and 157 and the second between 
residues 227 and 427 [10]. In the same study, two other 
non-nucleoside inhibitors of HIV-1 RT, thiazolobenzim- 
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idazole (TBZ) [11] and sulfoxamine [12], led to the sug- 
gestion that two other possible regions are crucial for the 
inhibition of both compounds. The first domain resides 
between amino acid residues 158 and 190 and the second 
between residues 203 and 224 [10]. 
In the current study, we have investigated the pattern 
of inhibition of two new compounds by a variety of 
enzymaticaily active chimeric HIV-1/HIV-2 RT mole- 
cules, in order to identify the regions in HIV-1 RT re- 
sponsible for inhibition. The compounds were identified 
through the US National Cancer Institute's high capac- 
ity screening program [13]. Through extensive structure 
activity relationship (SAR) studies, asimple derivative of 
oxathiin carboxanilide (OC, NSC 615985) [14] was iden- 
tified. The compound, designated UC-38 (NSC 629243) 
had improved activity and solubility characteristics over 
OC (McMahon et al., in preparation). The second com- 
pound, 2'-nitrophenyl phenyl sulfone, (NPPS, NSC 
624231), was identified through SAR analysis of a large 
group of biologically active diarylsulfones [15]. 
2. Materials and methods 
2.1. Reagents 
The two compounds used in this study were obtained through the 
Drug Synthesis and Chemistry Branch, National Cancer Institute. The 
chemical structures of the UC-38 (NSC 629243) and NPPS (NSC 
624231) are shown in Fig. 1. 
2.2. Enzymes 
HIV-1 and HIV-2 RTs were recombinant enzymes expressed in E. 
coli as described previously [16,17]. The enzymes were purified to ho- 
mogeneity by the method of Clark et al. [18]. 
2.3. Construction of HIV-IIHIV-2 RT chimeric proteins 
The construction ofthe chimeras designated A 1, A4, A6, A6/B6, B 1, 
B2, B6, C1 and C2 was described indetail previously [10,19]. The new 
chimeras C4, C5, C8 and C9 were constructed basically as chimeras C 1 
and C2 using the BspMI cassette mutagenesis system as described in 
detail elsewhere [20]. In all cases, in the expression plasmids we have 
replaced the DNA segments of the HIV-1 RT gene by the DNA seg- 
ments coding for the appropriate peptide sequences ofHIV-2 RT. The 
plasmids encoding either the wild-type HIV-1 RT and HIV-2 RT or the 
chimeric HIV-I/HIV-2 RTs were all introduced into the DH5~ strain 
of E. coli. Extracts of the bacterial strains expressing the wild-type or 
chimeric RTs were prepared as described previously [10,19]. 
2.4. Enzymatic assays 
The enzymatic assays for the RNA- and DNA-dependent DNA 
polymerase and RNase H activities of both wild-type and chimeric RTs 
were performed as described in detail previously [10]. In the inhibition 
studies, the IC50 values (concentrations of inhibitors leading to a 50% 
inhibition of the initial DNA polymerase activity) were calculated from 
the dose response inhibition curves for each recombinant enzyme from 
duplicate determinations. 
3. Results and discussion 
3.1. The effects of UC-38 and NPPS on enzymatic 
activities of purified HIV-1 RT and HIV-2 RT 
We have confirmed that both UC-38 and NPPS are 
specific inhibitors of HIV-1 RT. To this aim, we have 
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Fig. 1. The chemical structures of the non-nucleoside inhibitors of 
H1V-I RT used in the current study. 
analyzed the effect of both compounds on the catalytic 
activities of HIV-1 RT as compared with HIV-2 RT (Fig. 
2). The enzymatic activities analyzed were the RNA- 
dependent DNA polymerase (RDDP) activity (using 
poly(rA).olido(dT) or poly(rC).oligo(dG) assubstrates), 
the DNA-dependent DNA polymerase (DDDP) func- 
tion (with activated DNA as a template primer) and the 
RNase H activity. The purified enzymes were incubated 
with increasing concentrations of the inhibitors and the 
residual enzymatic activities were assayed and compared 
with the activities of control enzymes. Both the RDDP 
and DDDP activities of the HIV-1 RT are very sensitive 
to UC-38 and NPPS. The IC50 values calculated for UC- 
38 were about 2.5/,tM and 0.5 pM for the RDDP activity 
using poly(rA).oligo (dT) and poly(rC).oligo(dG), re- 
spectively, and 6 pM for the DDDP activity of HIV-1 
RT. The IC50 values for the inhibition of these activities 
by NPPS were about 19 /,tM and 9.5 pM (with 
poly(rA)-oligo(dT) and poly(rC), oligo(dG), respectively) 
for RDDP and 10/,tM for DDDP. This indicates that 
with both inhibitors the poly(rC)'oligo(dG)-directed 
RDDP activity is more susceptible to inhibition than the 
poly(rA).oligo(dT)-directed r action. As expected, the 
two inhibitors did not have any apparent effect on the 
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Fig. 2. The effects of UC-38 (A) and NPPS (B) on the DNA-dependent DNA polymerase, RNA-dependent DNA polymerase and RNase H activities 
of purified recombinant HIV-1 RT and H1V-2 RT. Increasing amounts of the inhibitors were added to the two enzymes in a solution of dimethyl- 
sulfoxide at a final concentration f 1%. The levels of enzymatic activities inhibited, as expressed in dNMP incorporated (for the DNA polymerase 
activities) or dAMP hydrolyzed (for the RNase H activity) in 30 min under the standard assay conditions [25] are as follows: for HIV-1 RT, 235, 
64 and 41 pmol incorporated with poly(rA), oligo(dT), poly(rC), oligo(dG) and activated DNA as substrates, respectively, for the DNA polymerase 
activities and 36 pmol for the RNase H activity. For HIV-2 RT, 180, 61 and 42 pmol for the poly(rA).oligo(dT), poly(rC), oligo(dG) or activated 
DNA-directed DNA polymerase activities, respectively, and 30 pmol for the RNase H activity. The residual activities in the presence of the inhibitors 
were calculated relative to the enzymatic activities of control enzymes that underwent similar treatments with no inhibitors. Filled symbols refer to 
HIV-I RT and open symbols to HIV-2 RT. Poly(rC).oligo(dG)-directed RDDP activity (circles); poly(rA).oligo(dT)-directed RDDP activity 
(squares); DNA-dependent DNA polymerase activity assayed with gapped-activated herring sperm DNA, prepared as described [16] (triangles); 
RNase H activity assayed with [3H]poly(rA)'poly(dT) (squares). Each value represents he mean of the results of two independent experiments. 
DNA polymerase function of HIV-2 RT, even at concen- 
trations above 300 pM (Figs. 2 and 3). Neither the 
RNase H activity of HIV-1 RT nor that of HIV-2 RT 
were affected to any detectable extent by any of the two 
substances tested (Fig. 2). This is not surprising, since 
none of the NNRTI or the nucleoside analogs of HIV 
RTs described so far had substantial effects on the 
RNase H activity of the RTs [21]. 
3.2. Inhibition of chimeric HIV-1/HIV-2 RT molecules by 
UC-38 and NPPS 
We have taken advantage of the total insensitivity of 
HIV-2 RT to a variety of non-nucleoside inhibitors to 
investigate the protein segments in HIV-I RT that are 
pivotal for the inhibitory activity of these substances. 
This was done by analyzing the relative sensitivity of a 
series of enzymatically active recombinant HIV-1/HIV-2 
RT molecules constructed from complementary protein 
segments from the two wild-type RTs. The sensitivity of 
the chimeric RTs is expected to result from the segments 
derived from only HIV-1 RT. We have previously used 
this approach to study TIBO, calanolide A, TBZ and 
sulfoxamine [10]. 
As shown in Fig. 2, there are basically few differences 
in the response of the DNA polymerase activity to either 
one of the primer templates used. Therefore, we have 
proceeded by analyzing the chimeric RTs with only 
poly(rC), oligo(dG) for assaying the DNA 
polymerase activity. The results with UC-38 and NPPS 
indicate that the chimeric HIV-1/HIV-2 RTs do not re- 
spond to these two novel inhibitors in a similar fashion 
(Fig. 3). A systematic nspection of the inhibition pattern 
of the hybrid HIV-1/HIV-2 RTs by UC-38 indicates a 
somewhat complex pattern. The chimeras designated A6 
and B2 are fully resistant to UC-38, whereas B6 is fully 
sensitive, suggesting that the specific interaction seg- 
ments are located between residues 203 and 226. Since 
chimera C2 is not susceptible to UC-38, this segment 
cannot span beyond residue 224. Hence, it is located 
between residues 203 and 224. However, the fact that 
chimera C1 is also resistant, strongly suggests the possi- 
bility that there is a second segment between residues 158 
and 190 that is also crucial to the interaction with the 
inhibitor. These results are similar to those obtained pre- 
viously by us with two other non-nucleoside inhibitors, 
TBZ and sulfoxamine [10]. 
A similar examination of the response pattern of the 
same chimeric RTs to NPPS reveals a difference in the 
putative interaction segments (Fig. 3). Unlike UC-38, the 
chimera B2 is fully sensitive to NPPS. All other chimeric 
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Fig. 3. The structures of the chimeric HIV-I/HIV-2 RTs and their 
sensitivity to UC-38 and NPPS. The construction of all plasmids used 
was described in section 2. Open boxes represent protein sequences 
derived from HIV-I RT and filled boxes sequences of HIV-2 RT. The 
extracts of the bacterial strains expressing the various proteins were 
diluted 5-fold in a solution containing increasing concentrations of the 
inhibitors in a final concentration of 1% dimethylsulfoxide and 
incubated with the appropriate substrates. The residual 
poly(rC) • oligo(dG)-directed DNA synthesis was determined 
as described [10,20] and the IC50 values were calculated as described in 
section 2. 
RTs respond to the two structurally diverse inhibitors in 
a similar manner. A comparison of the responses of chi- 
meras B1 and B2 to NPPS implies that the interaction 
sites reside between residues 93 and 202 in HIV-1 RT. 
Since both chimeras C1 and C2 are resistant o NPPS, 
the most likely explanation is that, as in the case of 
UC-38, there are two separate segments crucial for the 
inhibition. The first one resides in the same region as the 
comparable one inthe case of UC-38, namely between 
amino acid residues 158 and 190. However, the second 
one is probably different for NPPS and UC-38, being 
located between residues 192 and 202 for NPPS. It is 
interesting to note that the chinmera designated C2 is 
somewhat more sensitive to both inhibitors than are 
HIV-2 RT and other drug-resistant chimeric RTs (see 
Fig. 3). This may imply that the first putatative protein 
segment, that is required for the inhibition by the two 
compounds, is more important for inhibition than the 
second segment involved in this inhibition. 
It should be emphasized that the segments postulated 
for the interaction of UC-38 and NPPS with HIV-1 RT 
exhibit some similarity with the complementary ones in 
HIV-2 RT. Thus, in the first protein fragment important 
to the interaction of both inhibitors (residues 158 190), 
only 15 amino acid residues out of a total of 33 residues 
are different (suggesting that only one or several of these 
15 residues are candidates for interaction). Likewise, the 
second segment required for the inhibition by UC-38 
(residues 203-224) is comprised of only 12 amino acids 
(out of 22 residues) that are different. In the case of 
NPPS, the second putative peptide for the interaction 
(residues 192-202) contains 9 different residues (out of 
11 residues). 
The difference in the position of the second putative 
segment for specifying the susceptibility to either UC-38 
or NPPS may explain the slight disparity observed in the 
response of the DNA polymerase activities of HIV-1 RT 
to the inhibitors (Fig. 2). Generally, UC-38 is a better 
inhibitor of both RDDP and DDDP activities, as appar- 
ent from the lower IC50 values (Fig. 3). The inhibition of 
the RDDP activity by UC-38 is obtained at lower con- 
centrations relative to the DDDP function. On the other 
hand, NPPS inhibits the DDDP activity of HIV-1 RT 
slightly better, or to about the same extent, compared to 
RDDP activity. Taken together, it is possible that the 
difference in the response of HIV-1 RT to the two com- 
pounds stems from the putative interaction sites in the 
region that spans residues 192-224 (residues 192-202 for 
NPPS and residues 203-224 for UC-38). 
Recent X-ray crystallographic studies have resulted in 
the three-dimensional structure determination of HIV-1 
RT [22-24]. This has led to the conclusion that nevi- 
rapine, a typical NNRTI (that interacts with mainly 
Tyr 181 and Tyr 18s in HIV-1 RT) is buried in a deep hydro- 
phobic pocket at the base of the 'palm' subdomain of the 
protein, near but not overlapping the DNA polymerase 
active site. The putative protein segments crucial for the 
susceptibility to both UC-38 and NPPS are also located 
in the same 'palm' subdomain. Thus, the segment com- 
mon for the interaction of both inhibitors (residues 158- 
190) spans the a-helix designated czE and the fl sheets, f19 
and ill0. The second segment important for the inhibi- 
tion by UC-38 (residues 203-224) comprises the car- 
boxyl-terminal part of ccF, fll la and fll lb, whereas the 
second site for the interaction with NPPS (residues 
Z Rubinek et al. IFEBS Letters 350 (1994) 299 303 303 
192-202) is located in the amino-terminal portion of 0~F. 
For both inhibitors it may be possible that the com- 
pounds form a bridge between the two putative domains 
required for the inhibition by each compound. This in- 
teraction may inactivate the DNA polymerase catalytic 
site by mechanisms such as blocking the access of the 
template primer, preventing its binding to the protein, or 
by interfering with the incoming dNTP. 
The relatively complex interactions between various 
protein segments and UC-38 and NPPS were seen in the 
present study based on the pattern of inhibition of the 
chimeric HIV-1/HIV-2 RTs. Further detailed analysis of 
selected drug-resistant mutants will complement this 
study and identify the specific amino acid residues that 
are directly involved in the inhibition. It is also apparent 
that analysis of specific NNRTI-resistant mutants with- 
out screening chimeric HIV-1/HIV-2 RTs might result in 
overlooking other non-mutated regions that may also be 
pivotal for enzyme inhibition. This is based on the as- 
sumption that the resistance is usually not an additive 
phenomenon (when more than one protein domain is 
involved) and that modifying each domain independ- 
ently can lead to full resistance. The future availability 
of HIV-I RT variants resistant to UC-38 and NPPS will 
allow a more precise localization of the amino acid resi- 
dues that interact with these two novel inhibitors. 
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